• 1
    Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002; 53: 353359.
  • 2
    Perez CA, Camel HM, Askin F, Breaux S. Endometrial extension of carcinoma of the uterine cervix: a prognostic factor that may modify staging. Cancer. 1981; 48: 170180.
  • 3
    Noguchi H, Shiozawa I, Kitahara T, Yamazaki T, Fukuta T. Uterine body invasion of carcinoma of the uterine cervix as seen from surgical specimens. Gynecol Oncol. 1988; 30: 173182.
  • 4
    Noguchi H, Shiozawa K, Tsukamoto T, Tsukahara Y, Iwai S, Fukuta T. The postoperative classification for uterine cervical cancer and its clinical evaluation. Gynecol Oncol. 1983; 16: 219231.
  • 5
    Kamura T, Shigematsu T, Kaku T, Shimamoto T, Saito T, Sakai K, et al. Histopathological factors influencing pelvic lymph node metastases in two or more sites in patients with cervical carcinoma undergoing radical hysterectomy. Acta Obstet Gynecol Scand. 1999; 78: 452457.
  • 6
    Subcommittee on Radiotherapy of Cancer of the Committee on Hygiene of the League of Nations: rules of allocation of stages of cancer of the cervix., vol. 3, 1929.
  • 7
    Fagundes H, Perez CA, Grigsby PW, Lockett MA. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1992; 24: 197204.
  • 8
    Narayan K, McKenzie AF, Hicks RJ, Fisher R, Bernshaw D, Bau S. Relation between FIGO stage, primary tumor volume, and presence of lymph node metastases in cervical cancer patients referred for radiotherapy. Int J Gynecol Cancer. 2003; 13: 657663.
  • 9
    Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001; 19: 37453749.
  • 10
    Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000; 70: 207312.
  • 11
    Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004; 22: 21672171.
  • 12
    Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and paraaortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90–01. J Clin Oncol. 2004; 22: 872880.
  • 13
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 14
    Breslow N. A generalized Kruskal–Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika. 1970; 57: 579594.
  • 15
    Cox D. Regression models and life tables. J R Stat Soc. 1972; 34: 187220.
  • 16
    Tran BN, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol. 2003; 90: 572576.
  • 17
    Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987; 60(8 Suppl ): 20352041.
  • 18
    Prempree T, Patanaphan V, Viravathana T, Sewchand W, Cho YK, Scott RM. Radiation treatment of carcinoma of the cervix with extension into the endometrium: a reappraisal of its significance. Cancer. 1982; 49: 20152020.